564 related articles for article (PubMed ID: 30529816)
1. Glycyrrhetinic acid-conjugated polymeric prodrug micelles co-delivered with doxorubicin as combination therapy treatment for liver cancer.
Yang T; Lan Y; Cao M; Ma X; Cao A; Sun Y; Yang J; Li L; Liu Y
Colloids Surf B Biointerfaces; 2019 Mar; 175():106-115. PubMed ID: 30529816
[TBL] [Abstract][Full Text] [Related]
2. Co-Delivery of Paclitaxel by a Capsaicin Prodrug Micelle Facilitating for Combination Therapy on Breast Cancer.
Lan Y; Sun Y; Yang T; Ma X; Cao M; Liu L; Yu S; Cao A; Liu Y
Mol Pharm; 2019 Aug; 16(8):3430-3440. PubMed ID: 31199661
[TBL] [Abstract][Full Text] [Related]
3. Glycyrrhetinic Acid-Mediated Polymeric Drug Delivery Targeting the Acidic Microenvironment of Hepatocellular Carcinoma.
Zhang J; Zhang M; Ji J; Fang X; Pan X; Wang Y; Wu C; Chen M
Pharm Res; 2015 Oct; 32(10):3376-90. PubMed ID: 26148773
[TBL] [Abstract][Full Text] [Related]
4. Nanomicelles based on a boronate ester-linked diblock copolymer as the carrier of doxorubicin with enhanced cellular uptake.
Xu Y; Lu Y; Wang L; Lu W; Huang J; Muir B; Yu J
Colloids Surf B Biointerfaces; 2016 May; 141():318-326. PubMed ID: 26874117
[TBL] [Abstract][Full Text] [Related]
5. Glycyrrhetinic acid-decorated and reduction-sensitive micelles to enhance the bioavailability and anti-hepatocellular carcinoma efficacy of tanshinone IIA.
Chen F; Zhang J; He Y; Fang X; Wang Y; Chen M
Biomater Sci; 2016 Jan; 4(1):167-82. PubMed ID: 26484363
[TBL] [Abstract][Full Text] [Related]
6. Codelivered Chemotherapeutic Doxorubicin
Lan Y; Liang Q; Sun Y; Cao A; Liu L; Yu S; Zhou L; Liu J; Zhu R; Liu Y
ACS Appl Mater Interfaces; 2020 Jul; 12(28):31904-31921. PubMed ID: 32551517
[TBL] [Abstract][Full Text] [Related]
7. Tumor microenvironment-labile polymer-doxorubicin conjugate thermogel combined with docetaxel for in situ synergistic chemotherapy of hepatoma.
Zhang Y; Zhang J; Xu W; Xiao G; Ding J; Chen X
Acta Biomater; 2018 Sep; 77():63-73. PubMed ID: 30006312
[TBL] [Abstract][Full Text] [Related]
8. Acid-sensitive polymeric vector targeting to hepatocarcinoma cells via glycyrrhetinic acid receptor-mediated endocytosis.
Yan T; Cheng J; Liu Z; Cheng F; Wei X; Huang Y; He J
Mater Sci Eng C Mater Biol Appl; 2018 Jun; 87():32-40. PubMed ID: 29549947
[TBL] [Abstract][Full Text] [Related]
9. Ligand-directed reduction-sensitive shell-sheddable biodegradable micelles actively deliver doxorubicin into the nuclei of target cancer cells.
Zhong Y; Yang W; Sun H; Cheng R; Meng F; Deng C; Zhong Z
Biomacromolecules; 2013 Oct; 14(10):3723-30. PubMed ID: 23998942
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin.
Mezghrani O; Tang Y; Ke X; Chen Y; Hu D; Tu J; Zhao L; Bourkaib N
Int J Pharm; 2015 Jan; 478(2):553-68. PubMed ID: 25455765
[TBL] [Abstract][Full Text] [Related]
11. Polymeric micelles encapsulating pH-responsive doxorubicin prodrug and glutathione-activated zinc(II) phthalocyanine for combined chemotherapy and photodynamic therapy.
Gao D; Lo PC
J Control Release; 2018 Jul; 282():46-61. PubMed ID: 29673646
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin delivered by a redox-responsive dasatinib-containing polymeric prodrug carrier for combination therapy.
Sun J; Liu Y; Chen Y; Zhao W; Zhai Q; Rathod S; Huang Y; Tang S; Kwon YT; Fernandez C; Venkataramanan R; Li S
J Control Release; 2017 Jul; 258():43-55. PubMed ID: 28501705
[TBL] [Abstract][Full Text] [Related]
13. Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin.
Zhang X; Li J; Yan M
Drug Dev Ind Pharm; 2016 Oct; 42(10):1590-9. PubMed ID: 26942448
[TBL] [Abstract][Full Text] [Related]
14. A54 Peptide Modified and Redox-Responsive Glucolipid Conjugate Micelles for Intracellular Delivery of Doxorubicin in Hepatocarcinoma Therapy.
Liu N; Tan Y; Hu Y; Meng T; Wen L; Liu J; Cheng B; Yuan H; Huang X; Hu F
ACS Appl Mater Interfaces; 2016 Dec; 8(48):33148-33156. PubMed ID: 27934140
[TBL] [Abstract][Full Text] [Related]
15. Cleavable Multifunctional Targeting Mixed Micelles with Sequential pH-Triggered TAT Peptide Activation for Improved Antihepatocellular Carcinoma Efficacy.
Zhang J; Zheng Y; Xie X; Wang L; Su Z; Wang Y; Leong KW; Chen M
Mol Pharm; 2017 Nov; 14(11):3644-3659. PubMed ID: 28994600
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy.
Qi WW; Yu HY; Guo H; Lou J; Wang ZM; Liu P; Sapin-Minet A; Maincent P; Hong XC; Hu XM; Xiao YL
Mol Pharm; 2015 Mar; 12(3):675-83. PubMed ID: 25584860
[TBL] [Abstract][Full Text] [Related]
17. Ligand-directed stearic acid grafted chitosan micelles to increase therapeutic efficacy in hepatic cancer.
Yang Y; Yuan SX; Zhao LH; Wang C; Ni JS; Wang ZG; Lin C; Wu MC; Zhou WP
Mol Pharm; 2015 Feb; 12(2):644-52. PubMed ID: 25495890
[TBL] [Abstract][Full Text] [Related]
18. A pH-sensitive prodrug strategy to co-deliver DOX and TOS in TPGS nanomicelles for tumor therapy.
Xiong S; Wang Z; Liu J; Deng X; Xiong R; Cao X; Xie Z; Lei X; Chen Y; Tang G
Colloids Surf B Biointerfaces; 2019 Jan; 173():346-355. PubMed ID: 30316081
[TBL] [Abstract][Full Text] [Related]
19. Dual-Sensitive Charge-Conversional Polymeric Prodrug for Efficient Codelivery of Demethylcantharidin and Doxorubicin.
Wu Y; Zhou D; Zhang Q; Xie Z; Chen X; Jing X; Huang Y
Biomacromolecules; 2016 Aug; 17(8):2650-61. PubMed ID: 27384255
[TBL] [Abstract][Full Text] [Related]
20. Folate receptor targeted biodegradable polymeric doxorubicin micelles.
Yoo HS; Park TG
J Control Release; 2004 Apr; 96(2):273-83. PubMed ID: 15081218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]